PDGFRB and neoplasm: Sorafenib (Table 1.), an oral multi-targeted TKI, suppresses tumor growth and angiogenesis by targeting VEGFR1/2/3, PDGFR-β, c-Kit, FLT- 3, and inhibiting the Ras/Raf/MEK/ERK signaling cascade [239].